Current treatment for gastroesophageal reflux disease (GERD) confirms an unmet need in patients, based on slow onset of action and an inability to provide 24-hour gastric-acid suppression. Clinical data on AH234844 demonstrates a rapid onset of action, high potency, and prolonged duration of effect. The present study endeavors, in part, to compare lavoltidine to two GERD drugs, NEXIUM and ranitidine.
A three-part study in healthy male volunteers to determine the most effective of four different lavoltidine doses on gastric pH and to compare the most effective dose with NEXIUM (esomeprazole) 40mg for the inhibition of gastric-acid secretion and with ranitidine (300mg/day) for the amount of pharmacodynamic tolerance
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Enrollment
92
GSK Investigational Site
Randwick, New South Wales, Australia
GSK Investigational Site
Herston, Queensland, Australia
pH over 24hours
Time frame: over 24hours
%24 hours pH>4 Median gastric pH Adverse events
Time frame: over 24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.